Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series

被引：0
作者：
Robert S. Zhang
Allison Padegimas
Kathleen M. Murphy
Peter T. Evans
Carli J. Peters
Christopher M. Domenico
Mahesh K. Vidula
Paul J. Mather
Marisa Cevasco
Roger B. Cohen
Joseph R. Carver
Rupal P. O’Quinn
机构：
[1] University of Pennsylvania,Department of Medicine
[2] University of Pennsylvania,Division of Cardiovascular Medicine
[3] University of Pennsylvania,Division of Infectious Disease
[4] University of Pennsylvania,Department of Pharmacy
[5] University of Pennsylvania,Department of Cardiothoracic Surgery
[6] University of Pennsylvania,Division of Hematology
来源：
Cardio-Oncology | / 7卷
关键词：
Immune checkpoint inhibitor; Myocarditis; Infliximab; Cardio‐oncology; Pembrolizumab; Nivolumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
    Corrigan, Margaret
    Haydon, Geoffrey
    Thompson, Fiona
    Rajoriya, Neil
    Peplow, Claire L.
    Hubscher, Stefan G.
    Steven, Neil
    Hirschfield, Gideon M.
    Armstrong, Matthew J.
    JHEP REPORTS, 2019, 1 (01) : 66 - 69
  • [32] Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
    Park, Changhee
    Keam, Bhumsuk
    Yoon, Soon Ho
    Ock, Chan-Young
    Choi, Sun Mi
    Kim, Miso
    Park, Young Sik
    Kim, Tae Min
    Oh, Do-Youn
    Kim, Dong-Wan
    Kim, Young Whan
    Heo, Dae Seog
    Bang, Yung-Jue
    ESMO OPEN, 2019, 4 (06)
  • [33] Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis
    Tanabe, Junya
    Watanabe, Nobuhide
    Endo, Akihiro
    Nagami, Taichi
    Inagaki, Satoshi
    Tanabe, Kazuaki
    INTERNAL MEDICINE, 2021, 60 (04) : 569 - 573
  • [34] Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
    Abu-Sbeih, Hamzah
    Tran, Cynthia Nguyen
    Ge, Phillip S.
    Bhutani, Manoop S.
    Alasadi, Mazen
    Naing, Aung
    Jazaeri, Amir A.
    Wang, Yinghong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [35] Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature
    Stuby, Johann
    Herren, Thomas
    Schwegler, Naumburger Guido
    Papet, Claudia
    Rudiger, Alain
    SWISS MEDICAL WEEKLY, 2020, 150
  • [36] Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
    Feifei Wang
    Yang Liu
    Wei Xu
    Changjing Zhang
    Jianhong Lv
    Shaolin Ma
    Journal of Medical Case Reports, 15
  • [37] Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
    Wang, Feifei
    Liu, Yang
    Xu, Wei
    Zhang, Changjing
    Lv, Jianhong
    Ma, Shaolin
    JOURNAL OF MEDICAL CASE REPORTS, 2021, 15 (01)
  • [38] Clinical course and prognosis of immune checkpoint inhibitors-induced myocarditis: A case series
    Coustal, C.
    Palassin, P.
    Quantin, X.
    Lesage, C.
    Roubille, F.
    Guilpain, P.
    Faillie, J. L.
    Maria, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 151 - 151
  • [39] Case series: Immune checkpoint inhibitor-induced transverse myelitis
    Chatterton, Sophie
    Xi, Shuo
    Jia, Jessica Xi
    Krause, Martin
    Long, Georgina V.
    Atkinson, Victoria
    Menzies, Alexander M.
    Fernando, Suran L.
    Boyle, Therese
    Kwok, Samuel
    Duggins, Andrew
    Karikios, Deme
    Parratt, John D. E.
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [40] Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
    Aoki, Hiroshi
    Matsumoto, Naoki
    Takahashi, Hiroshi
    Honda, Masayuki
    Kaneko, Tomohiro
    Arima, Shuhei
    Ishii, Tomotaka
    Mizutani, Taku
    Masuzaki, Ryota
    Nirei, Kazushige
    Yamagami, Hiroaki
    Ogawa, Masahiro
    Kanda, Tatsuo
    Moriyama, Mitsuhiko
    Miura, Katsuhiro
    ANTICANCER RESEARCH, 2021, 41 (12) : 6225 - 6230
12345